METABIOMED.CO.,LTD
KOSDAQ
₩3,855.00
-0.90%
Delayed · cached 15 min
Fair value analysis
059210
METABIOMED.CO.,LTD
₩3,855.00
Close used for this calculation
₩8,899.87Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
68/100
Quality radar
Consensus fair value
₩8,899.87
Below FV▲ +130.9% against the close used
Model range ₩3,258.39 – ₩28,324.00
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear₩3,258.39Fair value₩8,899.87Bull₩28,324.00
FairClose
52-week traded range
52W low ₩3,490.0052W high ₩4,230.00
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading below the consensus fair value
METABIOMED.CO.,LTD closed at ₩3,855.00, 56.7% below the consensus fair value of ₩8,899.87 drawn from 10 valuation models.
Financial DNA score 68/100 — Strong. P/E of 8.8x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
₩8,693.87
+125.5%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=9%, r=10%, tg=3%, n=10yr
Graham Number
₩6,725.13
+74.5%
√(22.5 × EPS × BVPS)
EPS=438, BVPS=4589.29
Graham Formula
₩28,324.00
+634.7%
EPS × (8.5 + 2g) × 4.4 ÷ FD_Rate
g=20%, FD=3.3%
P/E Fair Value
₩8,760.00
+127.2%
EPS × 20x (sector P/E)
EPS=438, Sector P/E=20x
Peter Lynch (PEG)
₩8,843.22
+129.4%
EPS × Growth% (PEG = 1 is fair)
EPS=438, g=20.2%
EV/EBITDA
₩13,974.65
+262.5%
(EBITDA × 18x − Net Debt) ÷ Shares
EBITDA=21.43B
Dividend Discount (DDM)
₩4,454.84
+15.6%
D1 ÷ (r − g) where D1 = D0×(1+g)
D0=82.5, r=10%, g=8%
Book Value (P/B)
₩3,258.39
-15.5%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=4589.29, ROE=8.8%, g=6%, r=10%
Reverse DCF
₩3,855.00
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: -4.1% | Historical: 20.2%
Margin of Safety
₩9,844.31
+155.4%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=13125.75, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.